A
Alcista
Alcista · 25%AAPG
$58.30
Precio del escenario
$15.060
-0.245 (-1.63%)Al cierre
Loading chart…
- Máximo
- 16.070
- Apertura
- 15.060
- Precio medio ponderado por volumen
- 15.32
- Volumen
- 10.26K
- Capitalización
- —
- Mínimo
- 14.830
- Importe
- 157.17K
- EV/EBITDA, TTM
- -0.46
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
Análisis de IA of Ascentage Pharma Group International (AAPG)
MantenerAscentage Pharma (AAPG) is currently not a strong buy due to its recent performance and mixed analyst ratings. The stock is trading at $14.75, significantly down 44.07% year-to-date and 59.53% over the past year. The RSI is at 42.26, indicating it is near oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is at 10.06, which is relatively low, suggesting the stock may be undervalued. The main risk is the significant revenue decline of 38.9% year-over-year, which raises concerns about the company's growth prospects.
Métricas de valoración
El PER previsto actual de Ascentage Pharma Group International (AAPG) es 10.06, frente a su media de 5 años de -23.40.
Escenarios de precio de Alphio AI para AAPG
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
9.508-19NewsfilterAscentage Pharma Reports 29% Revenue Growth in H1 2026
5.008-02GlobenewswireAscentage Pharma Appoints New Executives to Strengthen Global Business
- 5.008-02Newsfilter
Ascentage Pharma Appoints New Executives to Strengthen Global Business
8.507-26GlobenewswireDr. Dajun Yang Named No. 3 on The Medicine Maker Power List 2026
- 8.507-26Newsfilter
Dr. Dajun Yang Named No. 3 on The Medicine Maker Power List 2026
Preguntas frecuentes sobre AAPG, respondidas por Alphio AI
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market. It operates in the Healthcare sector.
Ascentage Pharma (AAPG) is currently not a strong buy due to its recent performance and mixed analyst ratings. The stock is trading at $14.75, significantly down 44.07% year-to-date and 59.53% over the past year. The RSI is at 42.26, indicating it is near oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is at 10.06, which is relatively low, suggesting the stock may be undervalued. The main risk is the significant revenue decline of 38.9% year-over-year, which raises concerns about the company's growth prospects.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.